Related Experiment Videos
Dopamine-frusemide therapy in acute renal failure
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
|January 1, 1983
Summary
Low-dose dopamine and frusemide infusion effectively increased urine output and salt excretion in patients with acute renal failure (ARF) and hepatorenal syndrome, potentially reducing dialysis needs.
Area of Science:
- Nephrology
- Critical Care Medicine
Background:
- Acute renal failure (ARF) and hepatorenal syndrome are critical conditions often leading to fluid overload and electrolyte imbalances.
- Oliguria in these patients poses significant management challenges, frequently necessitating renal replacement therapy.
Purpose of the Study:
- To evaluate the efficacy of combined low-dose dopamine and frusemide infusion in managing oliguria in patients with ARF and hepatorenal syndrome.
- To assess the impact of this therapeutic approach on diuresis, natriuresis, and hemodynamic parameters.
Main Methods:
- Infusion of dopamine (3 µg/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours in 16 patients with ARF and 3 with hepatorenal syndrome.
- Monitoring of urine output, natriuresis, blood pressure, pulse rate, and central venous pressure.
Main Results:
- Significant diuresis and natriuresis were observed in all treated patients.
- No significant changes in blood pressure, pulse rate, or central venous pressure were noted during treatment.
- In hepatorenal syndrome cases, diuresis was re-established but oliguria returned upon cessation of infusion.
Conclusions:
- Combined dopamine and frusemide infusion is a promising strategy to manage oliguric patients, potentially mitigating fluid overload and hyperkalemia, thereby reducing the need for dialysis.
- This therapy represents a novel approach for hepatorenal syndrome, although its effects appear to be transient.